Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Iron-Deficiency | 4 | 2024 | 139 | 2.240 |
Why?
|
| Thrombosis | 5 | 2024 | 506 | 1.870 |
Why?
|
| von Willebrand Diseases | 2 | 2025 | 55 | 1.680 |
Why?
|
| Hemophilia A | 2 | 2024 | 31 | 1.510 |
Why?
|
| Anticoagulants | 7 | 2024 | 589 | 1.460 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 52 | 1.460 |
Why?
|
| Venous Thrombosis | 2 | 2021 | 168 | 1.210 |
Why?
|
| Hemorrhage | 2 | 2023 | 501 | 1.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 569 | 1.120 |
Why?
|
| Fibroblasts | 2 | 2021 | 861 | 1.000 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2022 | 52 | 0.910 |
Why?
|
| Postoperative Hemorrhage | 1 | 2025 | 81 | 0.900 |
Why?
|
| Iron | 2 | 2024 | 305 | 0.840 |
Why?
|
| Tonsillectomy | 1 | 2025 | 112 | 0.820 |
Why?
|
| Thrombolytic Therapy | 2 | 2024 | 208 | 0.800 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2021 | 106 | 0.780 |
Why?
|
| Health Information Systems | 1 | 2022 | 31 | 0.750 |
Why?
|
| Warfarin | 1 | 2023 | 123 | 0.740 |
Why?
|
| von Willebrand Factor | 1 | 2023 | 192 | 0.730 |
Why?
|
| Blood Coagulation Factors | 1 | 2021 | 32 | 0.720 |
Why?
|
| Thrombin | 1 | 2021 | 55 | 0.710 |
Why?
|
| May-Thurner Syndrome | 1 | 2021 | 4 | 0.700 |
Why?
|
| Dietary Supplements | 1 | 2024 | 448 | 0.650 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 99 | 0.650 |
Why?
|
| Factor X | 1 | 2020 | 4 | 0.640 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 115 | 0.640 |
Why?
|
| Anemia | 1 | 2023 | 354 | 0.620 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 151 | 0.620 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 189 | 0.620 |
Why?
|
| Blood Coagulation | 1 | 2020 | 126 | 0.600 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2019 | 20 | 0.600 |
Why?
|
| Lower Extremity | 1 | 2021 | 184 | 0.600 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2019 | 165 | 0.560 |
Why?
|
| Endothelial Cells | 1 | 2021 | 536 | 0.550 |
Why?
|
| Neutropenia | 1 | 2019 | 205 | 0.530 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 224 | 0.520 |
Why?
|
| Adolescent | 13 | 2025 | 20814 | 0.520 |
Why?
|
| Febrile Neutropenia | 1 | 2016 | 16 | 0.510 |
Why?
|
| Pediatric Obesity | 1 | 2022 | 416 | 0.500 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 635 | 0.500 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 205 | 0.490 |
Why?
|
| Infant | 10 | 2025 | 13210 | 0.480 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 598 | 0.460 |
Why?
|
| Child | 14 | 2025 | 26098 | 0.460 |
Why?
|
| Stroke | 1 | 2022 | 1041 | 0.430 |
Why?
|
| Bacterial Infections | 1 | 2016 | 324 | 0.400 |
Why?
|
| Humans | 25 | 2025 | 130931 | 0.400 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1611 | 0.350 |
Why?
|
| Prothrombin | 2 | 2021 | 24 | 0.340 |
Why?
|
| Infant, Newborn | 6 | 2025 | 8542 | 0.340 |
Why?
|
| Female | 12 | 2025 | 70755 | 0.290 |
Why?
|
| Retrospective Studies | 7 | 2025 | 17485 | 0.280 |
Why?
|
| Child, Preschool | 6 | 2025 | 14945 | 0.270 |
Why?
|
| Cell Line | 2 | 2021 | 2596 | 0.240 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 2558 | 0.220 |
Why?
|
| Iron, Dietary | 1 | 2024 | 15 | 0.210 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.210 |
Why?
|
| Factor XIII Deficiency | 1 | 2024 | 4 | 0.210 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2024 | 10 | 0.210 |
Why?
|
| Postthrombotic Syndrome | 1 | 2023 | 2 | 0.210 |
Why?
|
| Physician Executives | 1 | 2024 | 34 | 0.210 |
Why?
|
| Male | 8 | 2025 | 64823 | 0.210 |
Why?
|
| Thrombectomy | 1 | 2024 | 109 | 0.200 |
Why?
|
| Menorrhagia | 1 | 2024 | 81 | 0.200 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 46 | 0.200 |
Why?
|
| Ferritins | 1 | 2023 | 108 | 0.200 |
Why?
|
| Young Adult | 4 | 2022 | 10040 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1202 | 0.190 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 66 | 0.190 |
Why?
|
| Craniocerebral Trauma | 1 | 2024 | 140 | 0.190 |
Why?
|
| ADAM Proteins | 1 | 2022 | 84 | 0.190 |
Why?
|
| Aortic Diseases | 1 | 2024 | 189 | 0.180 |
Why?
|
| Hemoglobins | 1 | 2023 | 318 | 0.180 |
Why?
|
| Nutritional Status | 1 | 2024 | 302 | 0.180 |
Why?
|
| Carbohydrate Epimerases | 1 | 2021 | 1 | 0.180 |
Why?
|
| Ketone Oxidoreductases | 1 | 2021 | 2 | 0.180 |
Why?
|
| Bayes Theorem | 1 | 2023 | 306 | 0.180 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2021 | 7 | 0.180 |
Why?
|
| Thrombomodulin | 1 | 2021 | 18 | 0.180 |
Why?
|
| Factor V | 1 | 2021 | 15 | 0.180 |
Why?
|
| Factor Xa | 1 | 2021 | 15 | 0.180 |
Why?
|
| Carboxy-Lyases | 1 | 2021 | 14 | 0.180 |
Why?
|
| Antithrombin III | 1 | 2021 | 24 | 0.180 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2022 | 50 | 0.180 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12858 | 0.170 |
Why?
|
| Disease Management | 2 | 2024 | 559 | 0.170 |
Why?
|
| Proteolysis | 1 | 2021 | 189 | 0.170 |
Why?
|
| Factor VII | 1 | 2020 | 17 | 0.160 |
Why?
|
| Factor IX | 1 | 2020 | 17 | 0.160 |
Why?
|
| Thromboplastin | 1 | 2020 | 19 | 0.160 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 209 | 0.160 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 107 | 0.160 |
Why?
|
| Factor VIII | 1 | 2020 | 51 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2023 | 1225 | 0.150 |
Why?
|
| Cytoplasm | 1 | 2020 | 252 | 0.150 |
Why?
|
| Prognosis | 2 | 2025 | 4930 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 1 | 2020 | 312 | 0.140 |
Why?
|
| Peptide Fragments | 1 | 2021 | 776 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1680 | 0.130 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 155 | 0.130 |
Why?
|
| Gene Expression | 1 | 2021 | 1500 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2024 | 835 | 0.130 |
Why?
|
| Hematopoiesis | 1 | 2019 | 218 | 0.130 |
Why?
|
| Skin | 1 | 2020 | 549 | 0.130 |
Why?
|
| Models, Biological | 1 | 2021 | 1389 | 0.130 |
Why?
|
| Early Medical Intervention | 1 | 2016 | 30 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5257 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1270 | 0.120 |
Why?
|
| Standard of Care | 1 | 2016 | 134 | 0.120 |
Why?
|
| Triage | 1 | 2016 | 152 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2024 | 5096 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 741 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 206 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4008 | 0.100 |
Why?
|
| Adult | 3 | 2022 | 31541 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2019 | 1559 | 0.090 |
Why?
|
| United States | 1 | 2024 | 11718 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2016 | 6443 | 0.060 |
Why?
|
| Factor XIII | 1 | 2024 | 7 | 0.050 |
Why?
|
| Hemostasis | 1 | 2023 | 73 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 320 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 794 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2024 | 699 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1302 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3327 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2575 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2651 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 2866 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2022 | 3397 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 10901 | 0.020 |
Why?
|